Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine

Journal of Substance Abuse Treatment

Volumn 44, Issue 5, 2013, Pages 481-487

  Mark, Tami L ^a   Dilonardo, Joan ^b   Vandivort, Rita ^c   Miller, Kay ^a  

^a IBM WATSON HEALTH   (United States)

^b Health Services Research Administration ^*  (United States)

^c Health Resources Services Administration   (United States)

Author keywords

Buprenorphine; Integrated treatment; Opioid addiction; Pain; Prescription drug abuse

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; OPIATE AGONIST;

ADULT; ALCOHOLISM; ANXIETY DISORDER; ARTHROPATHY; ARTICLE; CHRONIC PAIN; COMORBIDITY; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DRUG DEPENDENCE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MENTAL DISEASE; MOOD DISORDER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84875079055     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2012.11.004     Document Type: Article

References (32)

1. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104:982-992.
2. Brands B., Blake J., Sproule B., Gourlay D., Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug and Alcohol Dependence 2004, 73:199-207.
3. Centers for Disease Control Unintentional drug poisoning in the United States Retrieved on May 15, 2010. http://www.cdc/HomeandRecreationalSafety/pdf/poison-issuebrief.pdf.
4. Clark R.E., Samnaliev M., Baxter J.D., Leung G.Y. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs (Millwood) 2011, 30:1425-1433.
5. Culliver J.D., Krouotil L.A., Dai L., Gfroerer J.C. Misuse of prescription drugs: Data from the 2002, 2003 and 2004 national surveys on drug use and health. DHHS Publication No. SMA06-1492, Analytic Series A-28 2006, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD.
6. Elixhauser A., McCarthy E.M. Clinical classifications for health policy research, version 2: Hospital inpatient statistics. Healthcare Cost and Utilization Project (HCUP 3) Research Note 1. AHCPR Pub. No. 96 0017 1996, Agency for Health Care Policy and Research, Rockville, MD.
7. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 2003, 349:949-958. Buprenorphine/Naloxone Collaborative Study Group.
8. Heit H.A., Gourlay D.L. Buprenorphine: New tricks with an old molecule for pain management. Clinical Journal of Pain 2008, 24(2):93-97. [Review. Erratum in: Clinical Journal of Pain, 2008, 24, 370].
9. Inciardi J.A., Surratt H.L., Cicero T.J., Kurtz S.P., Martin S.S., Parrino M.W. The "black box" of prescription drug diversion. Journal of Addictive Diseases 2009, 28:332-347.
10. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence 1995, 40:17-25.
11. Kosten T.R., Schottenfeld R., Ziedonis D., Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease 1993, 181:358-364.
12. Kautz C., Mauch D., Smith S.A. Reimbursement of mental health services in primary care settings (HHS Pub. No. SMA-08-4324) 2008, Center for Mental Health Services, Substance Abuse and Mental Health Services Administration, Rockville, MD.
13. Kraus M.L., Alford D.P., Kotz M.M., Levounis P., Mandell T.W., Meyer M., et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. Journal of Addiction Medicine 2011, 5:254-263.
14. Ling W., Wesson D.R., Charuvastra C., Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry 1996, 53:401-407.
15. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P., et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction 1998, 93:475-486.
16. Ling W., Mooney L., Hillhouse M. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug and Alcohol Review 2011, 30:300-305.
17. Mark T.L., Woody G.E., Juday T., Kleber H.D. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence 2001, 61:195-206.
18. Mark T.L. For what diagnoses are psychotropic medications being prescribed?: A nationally representative survey of physicians. CNS Drugs 2010, 24:319-326.
19. Mojtabai R., Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Affairs 2011, 30:1434-1442.
20. RED BOOK RED BOOK; Truven Health Analytics, Inc Retrieved on September 24, 2012. http://www.redbook.com/redbook/index.html.
21. Office of Applied Studies Results from the 2009 National Survey on Drug Use and Health: Volume II. Technical appendices and selected prevalence tables. NSDUH series H-38B, HHS publication No. SMA 10-4856 Appendices 2010, Substance Abuse and Mental Health Services Administration, Rockville, MD.
22. Paasche-Orlow M., Cheng D.M., Lloyd-Travaglini C., Saitz R., Samet J.H. Persistent pain is associated with substance use after detoxification: A prospective cohort analysis. Addiction 2007, 102:752-760.
23. Passik S.D., Hays L., Eisner N., Kirsch K.L. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. Journal of Pain & Palliative Care 2006, 20:5-13.
24. Reckitt Benckiser Pharmaceuticals Inc. (2010). Retrieved on January 19, 2012, http://www.suboxone.com/pdfs/SuboxonePI.pdf.
25. Rigg K.K., March S.J., Inciardi J.A. Prescription drug abuse & diversion: Role of the pain clinic. Journal of Drug Issues 2010, 40:681-702.
26. Rosenblum A., Joseph H., Fong C., Kipnis S., Cleland C., Portenoy R.K. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. Journal of the American Medical Association 2003, 289:2370-2378.
27. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National findings Retrieved on January 17, 2012. http://oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.cfm.
28. Trafton J.A., Oliva E.M., Horst D.A., Minkel J.D., Humphreys K. Treatment needs associated with pain in substance use disorder patients: Implications for concurrent treatment. Drug and Alcohol Dependence 2004, 73:23-31.
29. United Nations Office on Drugs and Crime UNODC World Drug Report, 2010. United Nations Publication, Sales No. E.10.X1.13 Retrieved on January 17, 2012. http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf.
30. United States Food and Drug Administration Postmarket drug safety information for patients and providers: Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) Retrieved on June 26, 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm191520.htm.
31. Victor T.W., Alvarez N.A., Gould E. Opioid prescribing practices in chronic pain management: Guidelines do not sufficiently influence clinical practice. Journal of Pain 2009, 10:1051-1057.
32. Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry 2011, 68(12):1238-1246. [Epub 2011 Nov 7].